Altimmune (ALT) Net Cash Flow (2010 - 2026)

Altimmune (ALT) has 17 years of Net Cash Flow data on file, last reported at $53.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 342.12% year-over-year to $53.8 million in Q1 2026; TTM through Mar 2026 was $48.5 million, a 262.34% increase from a year earlier, with the FY2025 full-year figure at $6.8 million, up 106.96% from the prior year.
• Net Cash Flow for Q1 2026 stood at $53.8 million, up from -$17.5 million in the prior quarter.
• Over the last five years, Net Cash Flow for ALT reached as high as $134.0 million in Q2 2025 and fell as low as -$121.9 million in Q3 2025.
• Historically, Net Cash Flow has averaged -$5.5 million across 5 years, with a median of -$10.4 million in 2022.
• Across the five-year window, Net Cash Flow tumbled 1202.89% in 2022 and soared 713.28% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$16.4 million in 2022, then jumped by 394.86% to $48.3 million in 2023, then sank by 88.7% to $5.5 million in 2024, then tumbled by 420.54% to -$17.5 million in 2025, then soared by 408.09% to $53.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $53.8 million in Q1 2026, -$17.5 million in Q4 2025, and -$121.9 million in Q3 2025.